Search Our Website:
menu
Dae Y. Lee
BIPC Logo

Dae Y. Lee

Shareholder

P: 973 424 5602
Newark, NJ
Wilmington, DE
 
 
REACH OUT ON LINKEDIN
DOWNLOAD vCARD
PRINT MY BIO
DATE
TITLE
CONTRIBUTORS
SERVICES & INDUSTRIES
MAR 3 2025

Johnson & Johnson Lawsuit Dismissal Changes Nothing! Health Plan Fiduciaries Must Stay Vigilant Over Pharmacy Benefit Management

DAE Y. LEE
FDA & BIOTECHNOLOGY PHARMACY BENEFIT MANAGER CONTRACT & AUDIT DEFENSE SERVICES
FEB 28 2025

FDA’s Removal of Semaglutide and the Evolving Tirzepatide Decisions: What Compounders Need to Know

DAE Y. LEE NATALIE P. CROW
FDA & BIOTECHNOLOGY
FEB 13 2025

How We Helped a New York Pharmacy Avoid PBM Network Termination – And What You Can Learn From It

ADAM C. FARKAS DAE Y. LEE
FDA & BIOTECHNOLOGY LIFE SCIENCES PHARMACY BENEFIT MANAGER CONTRACT & AUDIT DEFENSE SERVICES
JAN 27 2025

Tirzepatide, FDA, and Compounding: Understanding the Current Landscape

DAE Y. LEE NATALIE P. CROW
FDA & BIOTECHNOLOGY LIFE SCIENCES PHARMACY BENEFIT MANAGER CONTRACT & AUDIT DEFENSE SERVICES
JAN 22 2025

Navigating the FDA’s Final Interim Policy on Compounding with Bulk Drug Substances: A Guide for 503A Pharmacies and 503B Outsourcing Facilities

DAE Y. LEE NATALIE P. CROW TINA HU-RODGERS
FDA & BIOTECHNOLOGY LIFE SCIENCES PHARMACY BENEFIT MANAGER CONTRACT & AUDIT DEFENSE SERVICES
JAN 17 2025

Understanding the FTC’s Second Interim Staff Report on PBMs: What It Means for Plan Sponsors and Employers

ADAM C. FARKAS BRADLEY J. KITLOWSKI DAE Y. LEE
FDA & BIOTECHNOLOGY LIFE SCIENCES LITIGATION
JAN 16 2025

What Pharmacies Should Expect from PBMs in 2025: Audit Trends and Proactive Strategies

DAE Y. LEE
FDA & BIOTECHNOLOGY LIFE SCIENCES